Hippuric acid
|
Basic information |
| Metabolite name | Hippuric acid |
 | HMDB0000714 |
 |
C01586 |
 |
464 |
| Synonyms | hippurate acid; |
| No. of studies | 44 |
|
Basic information |
| Metabolite name | Hippuric acid |
| HMDB0000714 |
|
C01586 |
|
464 |
| Synonyms | hippurate acid; |
| No. of studies | 44 |
|
Relationship between Hippuric acid and depression (count: 44) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M004 | Type2 | CUMS + xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M004 | Type2 | CUMS + amitriptyline group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M007 | Type1 | CRS group vs. control group | Plasma | Wistar rat | Up |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + QZ group vs. CUMS group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M028 | Type2 | placebo group 4-week treatment vs. baseline | Serum | Human | Up |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Up |
| Study M053 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M053 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M069 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Down |
| Study M088 | Type3 | 6-h venlafaxine group vs. control group | Urine | Wistar rat | Down |
| Study M090 | Type1 | depressed group vs. control group | Urine | Human | Up |
| Study M090 | Type2 | depressed group 6-week treatment vs. baseline | Urine | Human | Down |
| Study M095 | Type2 | CUMS + XCHT group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M095 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Up |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Down |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + high dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M136 | Type2 | CUMS + moderate dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M475 | Type1 | dHB group vs. HB group | Urine | Human | Up |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Down |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M564 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Up |
| Study M577 | Type1 | female depression group vs. female control group, aged 20-29 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M672 | Type2 | SMG + paroxetine group vs. SMG group | Urine | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M840 | Type1 | casein-rich milk group vs. control group | Urine | Wistar rat | Up |
| Study M918 | Type1 | methamphetamine group vs. control group | Serum | C57BL/6 mouse | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M975 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M975 | Type2 | CUMS + high dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M975 | Type2 | CUMS + low dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Up |